September 16, 2019 Cover
Volume 97, Issue 36
On Sept. 17, 1999, Jesse Gelsinger died after receiving an experimental gene therapy from James Wilson’s lab at the University of Pennsylvania. That tragedy waylaid Wilson’s career and almost shut down the whole field. Wilson and his team put their heads down and spent the next decade searching for safer gene therapies. Today, his lab’s $70 million annual budget and bevy of biotech partnerships are fueling the gene therapy explosion.
The resurgence was never a sure thing.
Here’s how it happened.
Cover image:The polarizing pioneer guides a gene therapy renaissance
Credit: Matthew Bender
Scientists are paying more attention to the technique as a commercial instrument proves up to the task
When it comes to raising funds for growth, small instrument companies look to private equity firms, but sometimes reluctantly
Student-led protests call for government action to prevent catastrophic changes
Whether they’re fair or not, these established networks give some job seekers an advantage
Device could pave the way for miniature analytical instruments